Dit is Leaders in Life Sciences, een podcast waarin we op zoek gaan naar het verhaal achter de mens. We praten met leiders van nu en later over wat hun drijft, hun carrière en privéleven. Want door naar elkaar te luisteren komen we als individu en als sector verder. We willen onze partners hartelijk bedanken voor hun steun, dat zijn Pivot Park, Pedersen & Partners en Johnson & Johnson The Netherlands. Te gast in deze aflevering, Christoph Korpus. Uw host is Henk Jan Out.
Henk Jan Out
Today, our guest is Dr. Christoph Korpus, the CEO of Byondis B.V. He was trained as a pharmacist in Germany, received a PhD in pharmaceutical technology, and was a practitioner pharmacist for more than four years in Munich. He joined Merck, the German Merck, in 2016 as a laboratory head, and soon afterwards became active in managing alliances and business development of that company. Did an executive MBA at Kellogg in the United States. And in 2025, he joined Byondis as Chief Business Officer. And as from March this year onwards, as CEO. So thank you for joining us, Christoph, today and to talk about Byondis/a company that I’ve heard referring to as the best kept secret in the Netherlands. So this is your chance to change that and tell all about it. I’m sure you will do that. But let’s get started first. Your own career. You were trained as a pharmacist. You practiced for some time, but then you joined the pharmaceutical industry. What made you change your mind?
Christoph Korpus
Yeah, thanks for having me. Pleasure to be here. Indeed, so I studied pharmaceutics right after I finished my military service at that point in time in Germany, that was still mandatory. And the beauty about that study is, as I always say, you learn a lot and you know everything a little bit. But you don’t know anything to the full extent, right? So, this is really kind of a generalistic kind of study, which is nice because you get to see the full value chain. You get to see how medicines are being researched, developed, and then also how they are being made eventually, which is quite important because Byondis, we are fully integrated, which means that we have our own manufacturing capabilities. So, that helps me currently quite a bit to understand what we’re doing, right? What all the colleagues are doing in the different departments. And then coming back to your question, why did I eventually join the industry, is that the work as a pharmacist is interesting, but it’s not very, at least for me, it was not fully fulfilling my scientific enthusiasm and I wanted to do more, right? So I really wanted to go deeper in the science bit and understand better how medicines are being developed, how they are being researched. And that is actually done in the industry. Some colleagues, some people actually think that research happens in academia. That is true to a certain extent. But a quite big portion is happening in biotech and industry. And this is when I decided to join the industry.
Henk Jan Out
Is there a lot of attention to drug development generally in the pharmacy-education in Germany?
Christoph Korpus
Not that much. It’s more about controlling the quality of a product, making sure that the concentration that is on the label is actually also in the medicine. It’s a lot about making sure that the drug is safe, that you at the end give to the patient, and that the quality is correct. We have limited courses, so to speak, on drug discovery or things like that. That’s correct. It’s not an integral part of the education.
Henk Jan Out
Right. But then, so you joined Merck, which I suppose is a logical choice with one of the biggest pharmaceutical companies in Germany, worldwide actually. You became head of a laboratory. What exactly did you do there?
Christoph Korpus
That’s an interesting question, but we first can maybe even take a step back, right? So I studied pharmaceutics, but then afterwards, I did not immediately join the industry. I decided to do a PhD in pharmaceutical technology, and that was around…
Henk Jan Out
You did that next to your practicing as a pharmacist?
Christoph Korpus
Afterwards, yes.
Henk Jan Out
Afterwards, it was full time PhD?
Christoph Korpus
Exactly. It was three and a half years, University of Munich, beautiful city, you know, very nice time there doing my PhD. And of course, you have to also earn your living, right? Because that is not a highly paid job. So I used my license to work on the weekends, you know, and also during the night shifts to make sure that, you know, patients get their medicine. And this is what I did.
Henk Jan Out
So you did have this scientific interest to doing the PhD.
Christoph Korpus
Yes, yes, absolutely. Even though I have to be honest, the PhD in pharmaceutical technology was more like a pragmatic thing to do, right? Because if you want to enter the industry, that is a very, very good degree to get because those jobs are very specialized, making the drugs. And I did it in a very technical area of lyophilization, which is all about making stable and high quality drugs.
Henk Jan Out
So it was part of a plan. You wanted to go to industry and said, let’s do a PhD first.
Christoph Korpus
Yes, exactly. This was the case. Even though I have to say that I’m much more a scientist at heart. And that is what I realized during that time and also afterwards. Because the real interesting piece for me is about how do drugs work? It’s called pharmacology, right? Where do they go? What is the mode of action? And this is what I realized, and I’m happy that I can do that now much more than I used to do. But it was a very good stepping stone to enter the industry.
Henk Jan Out
Right. So then you were indeed hired by Merck. You entered as a laboratory head. So what was your job there?
Christoph Korpus
That was an interesting time because I had a small team and we were doing development, but not drug development. We were doing excipients. For example, that is in a sterile drug product that is not the active pharmaceutical ingredient. This is what we did there. And yeah, we looked how can we stabilize drugs? How can we make them more, not more efficacious, but how can you make sure that more of the API reaches certain parts of the body, for example, that’s contracted?
Henk Jan Out
The active pharmaceutical ingredient, API. Yes. And that is one of those things that we all take for granted, don’t we? It is really very important to have all those excipients well defined and well tested. Lots of people don’t realize that, I think.
Christoph Korpus
No, exactly. You can do your PhD in those areas, right? So people always think about drug development in a different manner, but these are very important pieces. And that is what I also enjoy doing there. What I also learned at that time is that I also have a fable, so to speak, for the economic side of things. So the business cases for each project, we looked into does it make sense to pursue that project? And this is then when I also realized I want to do my MBA at a certain point in time. And that was a very nice thing that went along with the job so I could do that in parallel.
Henk Jan Out
Right. So you shifted more and more into the more managing of things rather than actually being in the lab and working with excipients or with active pharmaceutical ingredients. You wanted more into the management of the company.
Christoph Korpus
Yes. Yeah. I would not say the management of the company because that is a very big company, right? But certainly the tasks were more managerial at that point in time and less. I think I spent a very, very limited amount of time actually in the lab. I was more managing the team and making sure the projects went ahead. And that is also a skill that you have to have and that you have to enjoy.
Henk Jan Out
Yeah. So alliance management, business development, not marketing, for example.
Christoph Korpus
No, no, no, not marketing. That is a very different…
Henk Jan Out
And you say that very clearly. Don’t want to go into marketing.
Christoph Korpus
No, no, no. Understand, right? If you do BD&L, that is the technical term, business development and licensing, many colleagues refer to BD as business development. Oh, that’s sales, right? Which is not the case, right? So it’s really about intellectual property, how to make sure to monetize that intellectual property, and then you can agree with another company to acquire those rights to a certain medicine. And it’s all with the emphasis is really on the licensing part of it.
Henk Jan Out
How do you learn that?
Christoph Korpus
There is no course out there on how you can learn that. So it’s really training on the job. You can learn certain skills that you need for the role. So you have to, you know, the PhD helps, right? An MBA helps, of course. But there is a ton of working on the job. What did help quite a big time was during my studies at the Northwestern University in conjunction with WHU University and Vallendar, which is close to Frankfurt. I did a course on negotiations. That was quite something. It was really helpful, not only in my private life, but especially also for work.
Henk Jan Out
So, what’s the big secret behind negotiations? What is it that you should do or should not do?
Christoph Korpus
There are so many things, right? But the one thing that is really hardcoded in my brain after the course, because the trainer, Victoria Medvec, she’s really good, she’s brilliant. I would say she always says this one very easy term, and that is: say it, don’t send it. Which basically means if you negotiate, never send an email, including a nonbinding offer or terms. Really, you know, pick up the phone. You get so much information, you know, in brackets between the lines when you speak to somebody instead of just writing an email. So I think this is the one thing that really stood out.
Henk Jan Out
Yeah. It’s probably not only for negotiations, but generally probably anyway a better idea.
Christoph Korpus
Life would be so much better, right?
Henk Jan Out
Yeah, absolutely. Okay. So, yeah, alliance management. And then business development, what was the major? Was it two different things that you did over there, or was it part of the same departmental responsibilities?
Christoph Korpus
Oh, yeah, it’s very much, you know, it’s very similar to a certain extent, and then not. So, alliance management, there the emphasis is really on managing, right? So, you make sure that a contract that has been crafted before by the transactions team, for example, is honored by both parties. So, you make sure that, you know, the terms that are in the agreement are followed. You resolve conflicts. Ideally, before they come to the surface. So, this is really a very strong negotiations as well as interpersonal skill set that you need for the role. And you can learn a lot, right? So, before you get into crafting agreements, you get to manage them and then you get to understand them. So, you know how those terms are being interconnected in an agreement, which can sometimes be very complex, right? So sometimes it’s almost a hundred pages, a document that you have to take care of. Care of, and then there is the governance section in there, which is mainly the one for the alliance manager. So you learn a lot in that role that then enables you later on to work more on crafting those agreements, which is then the transactional role that I did afterwards.
Henk Jan Out
Did you see a shift in that? I mean, I think many companies went into more external alliances, working with others rather than doing everything yourself.
Christoph Korpus
Yes, if you look overall in the percentages of blockbuster drugs that actually made it to the market and became a blockbuster drug, I think the majority of those were not developed at the marketing machine, so to speak, that at the end of the day then pushes it to the market and makes sure that this innovation reaches the patient, which is also very important. But in most cases, those originate from biotechs and sometimes also from academia.
Henk Jan Out
Right. So, business development, Merck, then Byondis, how did you end up there? And why was Byondis the next step? Were you headhunted or were you looking outside to go to another company? What was your consideration to change?
Christoph Korpus
I got contacted by Pedersen & Partners, right? That is at the end of the day, the agency that you might also be familiar with. And they just reach out in a very kind way. And you mentioned initially that Byondis is the best kept secret of the Netherlands. And that is very much true. So during that process, I realized what that company is doing and the breadth of the science, as well as the assets, the physical assets, including a full-blown ADC, as well as antibody manufacturing. Which to me is unprecedented in a biotech in Europe in that setting. And that is connected to such a low profile that the company kept because of its history. So, absolutely not being in the public domain as much as we deserve to, actually, which is also the part of why I’m here today, right? And that is something that I realized quite immediately and made me very enthusiastic to join the company and to help them, to help us, I have to say by now, on our journey to become one of the leading ADC companies in Europe and if not in the world.
Henk Jan Out
That’s one of the reasons why many people are unfamiliar with it. It might be that it is, you know, it’s not on stock exchange markets where you don’t read about it, so it’s privately owned.
Christoph Korpus
Yes, exactly. Since its origin, actually. So Jacques Lemmens, who is our majority shareholder, who is our founder, still very much involved in Byondis to date, he founded the company. He grew it from a university spin out, so to speak, here in Nijmegen at the Radboud University. In the early 80s, up to one of the biggest generics companies in Europe, which is called Synthon. And then in 2007, they started the biopharmaceutical activities, which led to the formation of Byondis at the end of the day in 2012, which was called Synthon Biopharmaceuticals at that time, and then got rebranded to Byondis. This is the name that we have since 2019. And you’re right. That history being private, two shareholders as of today, Jacques Lemmens, Huub Sanders. This is the uniqueness about it that we have those capabilities, but not the, I wouldn’t call it the reputation, but not the public relations that any other VC backed biotech would have big time giving those capabilities that we have. And that is something that we have to really put out there more loudly, I have to say.
Henk Jan Out
Yeah, yeah, yeah. We’ll come back to that in a minute, what the strategy for the future is. It’s the, yeah, Synthon was then sold, I suppose.
Christoph Korpus
Yes.
Henk Jan Out
And actually, we had Anish Mehta, the CEO of Synthon, also here in the podcast. And yeah, Byondis then on its own. And you were developing at the time an antibody drug conjugate, was submitted to the FDA, but unfortunately was not registered there.
Christoph Korpus
Yes.
Henk Jan Out
So what can you, we don’t have to develop on it a very long time, but can you briefly say what happened?
Christoph Korpus
Yeah, I mean, drug development is per se a risky business, right? And the drug that you’re referring to was an HER2 targeted antibody drug conjugate using a very powerful payload that is the chemotherapy that is attached to the antibody drug conjugate at the end of the day. And if you look at the statistics, right, even a phase three trial, statistically from a probability of technical and regulatory success, it’s still a flip of coin, right? So even though you have invested up until that point hundreds of millions of euros, it is still a 50/50 chance that that specific drug makes it to the market. And that is what happened at the end of the day, right? So we did not make it. We did not get the approval. You can argue about statistic significance. You can argue about COVID having played a role in enrollment. You can argue about a competitor developing a similar drug at that point in time, which is now the best selling ADC out there. So, a lot of reasons. At the end of the day, I guess it was a very bold move for a comparably small company as Byondis was at that point in time to do it alone, right? And that to me is, I think, the biggest learning that we said you can fail for numerous reasons, but you can reduce that risk significantly if you share risk early on and if you look into partnering a bit earlier than we used to do in the past.
Henk Jan Out
Has that development completely stopped, or are you still trying to get it registered somewhere in Europe or in other countries?
Christoph Korpus
No, that development has stopped already in 2024. We have now much more promising platforms that we focus all our efforts on these days.
Henk Jan Out
So that was actually quite dramatic for the company, wasn’t it? There were some people that had to be laid off.
Christoph Korpus
Yes.
Henk Jan Out
So what is Byondis right now? So we’re now 2026. How many people do you have employed?
Christoph Korpus
Yeah. So we are really an ADC powerhouse in the making, so to speak, right? So, we are doing ADCs since more than 20 years. We have more than 200 colleagues focusing on really innovative antibody drug conjugate platforms, each of which tackles a very specific challenge that currently, you know, anti-cancer drugs, I have to say, are facing. We have some of those ADC platforms that are tackling specific challenges for the ADC in that area, and others more on the broader anti-cancer medicines field. And this is where we are now pulling all our resources to because what you still see out there is that current therapies run into issues at the end of the day because the cancer, from a complex biology side of things, it’s a smart beast because it finds its escape mechanisms, right? And what we see currently out there is that innovators and biotechs are still trying to tackle the cancer with the same chemotherapy. And if you look at the ADC space, the overwhelming majority relies on two different targeted chemotherapies at the end of the day. And the statistic is clearly showing that those patients do not benefit after they have seen once the treatment. So we need to have new ideas. We have to come with fresh payloads that can really help those patients in need. And this is what we are doing.
Henk Jan Out
Behind these ADCs? Why is Byondis so good at it?
Christoph Korpus
Yeah, that is a very interesting question. So, the history behind the ADC goes way back, right? So, those molecules have been designed 20, 30, sometimes even 40 years ago. And the idea, really, in a very simplistic way, is to put an address label on the chemotherapy and then send the chemotherapy directly to the cancer cell instead of damaging the healthy cell, right? From Paul Ehrlich. And that is what we are pursuing still today.
Henk Jan Out
And many other companies as well, I suppose.
Christoph Korpus
And many other companies as well.
Henk Jan Out
Lots of competition here.
Christoph Korpus
Absolutely. It’s a hot area. I think it was ESMO 2024, so the European Cancer Congress, where it was laid out that this is the decade of the ADCs. So 2020 until 2030, you see that this drug class is really transforming the standard of care. We are seeing, for example, HER2 moving into first line treatment for breast cancer. And it’s really adding benefit to cancer patients. Yet you still have those issues with cancer getting resistant to those therapies. So you need to come with something else. And you also see quite a bit of ADC and chemotherapy ending up in the healthy tissue. And then you see severe side effects. So this is also something that we at Byondis have our own platform to overcome.
Henk Jan Out
Because I did my little research on this, but I read that there are more than 400 ADCs in global development with more than 200 in clinical trials.
Christoph Korpus
Yeah, but you know, the sad side story of those numbers is that out of those 400, I would bet more than 350 are having the same chemotherapy attached to them. So I would say, unfortunately, the vast majority of those molecules will all be stopped sooner or later.
Henk Jan Out
So they all chose more or less the same chemical structures and the same small molecules for those developments.
Christoph Korpus
Yes. This is the result of what is called the herding effect in the pharmaceutical industry. So, as soon as you realize one mode of action really works nicely, everybody wants to have it, right? And you see this over and over. It used to be the checkpoint inhibitors. You know, at a certain point in time, Keytruda paved the way. And then, you know, we had, I don’t know, 6, 10, 15 checkpoint inhibitors.
Henk Jan Out
Yeah, I lived for a while in China, and I remember that there were about 40 or 50 companies were doing the same thing.
Christoph Korpus
Exactly. And it’s happening again, right? So we’re seeing this now. And this is really kind of, I hope, the peak of that herding effect that we do see currently, where unfortunately a lot of those developments will be stopped. And then we see, and this is what’s happening in the recent weeks, actually, you see that pharma companies are now acknowledging that fact and they are acquiring companies that are doing novel payloads so that you can then come with something like that.
Henk Jan Out
So why have they all chosen the same payloads then? Because there are so many different chemical agents that I suppose are suitable candidates for these ADCs.
Christoph Korpus
Because it’s incredibly complex to develop it, which is really, it’s more than only med chem, right? So you have to run more than one med chem campaign to come up with a good payload at the end. You have to look at potency, it has to be in a certain, ideally sub nanomolar potency range. But then you have to also be able to make it a linker drug. So you have to be able to link it to the antibody. And this is a science in itself. So, what you just, the number that you just shared, those are, in my view, a lot of Me-Too products where other companies changed a little moiety here and there on the payload, so on the chemotherapy, and then made their own version of something that is already existing. And we have to move beyond that, right? So, we have to really be more ambitious in coming up with new payloads because patients need it. Thousands of patients in a couple of years that are currently on drug on the existing ADCs, and there we need to find something else.
Henk Jan Out
Byondis, obviously, doing things differently.
Christoph Korpus
Yeah.
Henk Jan Out
So you have unique payloads, or are you also working on this? Okay. And I think you already more or less did it. One of the big strengths of your company is that you have this combination of manufacturing plants for monoclonal antibodies and also a separate antibody drug conjugation facility, right?
Christoph Korpus
Yes.
Henk Jan Out
And that’s something that the other big companies involved, GSK and Pfizer and others, they must have similar facilities, or is something Byondis that you do differently?
Christoph Korpus
No, absolutely. But you mentioned it, right? These are big pharma companies. They do have those capabilities. Most of our biotech peers rely on contract manufacturers for that type of work, which is obviously fair to do, right? What normally venture capital firms require you to do, right? So they don’t want to invest in assets and physical assets. But we have that, and that gives us certain advantages in terms of speed, which is very important, and most importantly, in terms of flexibility. So we can very easily shift priorities between projects because, you know, cell line development is a lengthy process. We have the means to change when we see shifting priorities. And it’s also very interesting for potential partners to work with us because we have those capabilities, we can allow quick turnaround times when we want to test molecules and we first have to make them. So it’s a very unique setting.
Henk Jan Out
Right. So if you look at your pipeline slide on the website, so you have, yeah, you’re not in the clinic right now, right? It’s all preclinical work that you’re currently doing.
Christoph Korpus
Yes, exactly. We took the deliberate decision to stop our clinical programs. We still had one program in the clinic which was based on the legacy payload, duocarmazine, very potent payload. We took the decision to stop that program and also a monoclonal antibody targeting SIRP alpha, which we also had there, where we said we now want to really shift our focus on the areas that matter most and where we can make the biggest difference in the anti-cancer field, so to speak. And this is what we are doing. And because of that, we are preclinical, but only for a couple of few months. I want to emphasize that. We’re doing something very interesting and something very motivating for me and all my colleagues. We are pushing a novel antibody drug conjugate having a unique payload into the clinic next year. So we will be in the clinical arena back in 2027.
Henk Jan Out
Right. Can you say something more about that? So that’s the indication that you’re envisioning?
Christoph Korpus
Yes, yes, sure. So we did not yet disclose the target of the antibody drug conjugate, but I can share so much that we are going for solid tumors. So we are having a validated target with our antifolate payload, which is the linker drug that we have patented, which is unique in a sense that it can tackle those cancer cells when they have already seen the commonly used antibody drug conjugates. And we can powerfully, in a preclinical setting, show that this is a very, very important way to help those patients potentially, which is what we all. Course, want to prove then next year.
Henk Jan Out
As a sort of a second line option or?
Christoph Korpus
This is where you normally start. Yeah, you normally start in later line therapy. It depends a little bit on the clinical setting, which indications you go after. We will do that in a basket trial and then see, you know, where we find the signal, we will expand. We already have a good idea because the beauty about that payload class that we have, the mode of action as such is validated. Actually, it’s the oldest chemotherapy that is out there, invented by Sidney Farber in Boston in the year 1948. So it has been used in a systemic way in patients and it has worked as one of the first chemotherapies quite nicely. But because of the side effects that patients get and they suffer from by receiving that drug systemically, the use is limited. And what we now do is that we want to reintroduce that mode of action class, which is orthogonal. Which is different than what is out there currently, but reduce the side effects and thereby have a longer duration of treatment and hopefully also a better survival at the end of the day for those cancer patients.
Henk Jan Out
Right. So that’s basically a platform of antifolate ADCs that you’re pursuing.
Christoph Korpus
Yes, exactly.
Henk Jan Out
There, you also on the slide, I saw on the website, you also do masked therapeutics.
Christoph Korpus
Yes.
Henk Jan Out
So what’s that?
Christoph Korpus
Yes, that is a very interesting concept because, as I said initially, the claim to fame, so to speak, for antibody drug conjugates is really the targeted manner, right? So putting the address label on the chemotherapy and then sending it to the cancer cell and having less of it in the healthy tissue. But that promise is not fully fulfilled by the current ADCs out there because those targets, so the antennas basically on the cancer cell, they are also to a certain extent expressed on healthy tissue. So you always have a little bit of chemotherapy going into healthy tissue, and then you see side effects as you do see in a similar or sometimes less worse…
Henk Jan Out
You need your antibodies to really be directed at a unique receptor.
Christoph Korpus
Yes, exactly.
Henk Jan Out
At the cancercell.
Christoph Korpus
Exactly.
Henk Jan Out
But they don’t exist or they are…
Christoph Korpus
Yeah, you can argue. I mean, there are some out there, but the ideal target, so to speak, that is only 100% expressed on the cancer and 0% expressed on the healthy tissue, I think somebody would have to show that to me, at least to my knowledge it’s not existing. So, what does this masking technology now do? That is a very interesting concept because it makes the ADC even more targeted because the cancer, as such, has what is called a tumor microenvironment. So, it’s the surrounding of the tumor, so to speak. There you have certain chemical moieties present, which are called proteases. And what they can do is they can cut amino acids. So, what we did is we put a big chain of amino acids, so to speak, around the antenna, which is trying to be very specific, so it does not bind to the healthy tissue when it is in the blood circulation. It really relies on those proteases to be present around the tumor. So only then the what we call mask gets cleaved off, and only then the antibody drug conjugate can really bind to its target. So it’s a second layer, so to speak, of specificity at the end of the day, which you can then further enhance by smart linker design, which we also do. So, this is kind of a triple layer security system that we put into the ADC to be a bit more specific than what we see out there currently.
Henk Jan Out
Right. So, then you can completely get rid of all your off-target effects.
Christoph Korpus
Yeah. In an ideal way.
Henk Jan Out
But that’s something you’ve demonstrated in animal models, I suppose.
Christoph Korpus
Yes. Very powerfully, we can show that this really, really increases what is called the therapeutic index. So, the difference between the minimum efficacious dose and the maximum tolerable dose. But at the end of the day, you always rely on mice and dogs and monkeys to test your molecules. And you have to do that before you go into a first in human study. But you will only know at the end of the day once you’re in the clinic. And we’re doing that in the very near future.
Henk Jan Out
All right. And the third platform is the phosphonate ADCs.
Christoph Korpus
Yep. Yeah. That is a beautiful example of the very, very good science that is happening at Byondis on this, because what the colleagues did is they looked at the human immune system to fight cancer, which is pretty interesting because we touched upon it those checkpoint inhibitors, they really have transformed the standard of care for cancer therapy, but only for a subset of patients. So I think only 20 or 30 percent of cancer patients really benefit from those drugs, and that is a pity. So that is because cancer is smart. It just downregulates one of the address labels, so to speak, on the outer cell of the cancer cell on the outer surface. So we tried to find a way that does not rely on that antenna, which is called MHC I. And we looked at the human immune system and we saw a mode of action that can be used as an ADC. And the interesting part is what happens when you have an infection in your immune system or in my immune system. In the infected cell, there is a small chemical moiety naturally being concentrated up, and these are phosphonates. And that chemical moiety intracellularly then changes the antenna on the outside of the cancer cell, which is a specific receptor. And then your innate immune system can attack that cancer cell. And we use that mode of action. It’s an ancient mode of action part of the human immune system. And we made a linker drug, so we made a payload out of that phosphonate that normally goes up in your infected cell. And we can very nicely show preclinically that we can elevate those levels via an ADC in a cancer cell. So we are kind of infecting the cancer cell, and then your immune system does the job to fight the cancer.
Henk Jan Out
So that mechanistically is different than your concept of a normal ADC.
Christoph Korpus
Exactly.
Henk Jan Out
So you’re trying to train your own immune system to actually get rid of the cancer cells rather than attacking them with particular chemicals.
Christoph Korpus
Yeah, yeah. We believe that at the end of the day, you have to prolong life, right? So that is the overall goal, what we are doing. And then you have to mix and match. So you have to have something that hits the tumor hard and that shrinks the tumor. But then you have to get the immune system going and you have to make sure that you come to a durable response and really extend the progression free survival and ultimately overall survival of those patients. And that is a nice approach where you can also think about combining two different sorts of payloads in one molecule, which is also something that we can do at Byondis.
Henk Jan Out
Right. So, this sounds very scientific, very basic, and very interesting. So, how confident are you that you can actually bring it forward to the clinical stage, all those platforms? You’ve already mentioned one of them is already entering the clinical stage next year. Also, the other ones, how far progressed are you?
Christoph Korpus
We are in late-preclinical development. And as I said initially, we learned from the past, right? So we want to share risk. So we are perfectly capable of developing at least one lead asset out of each of those platforms towards the clinic ourselves. But we want to do this in a staggered and mindful fashion. So our focus now is on finding partners that help us to share risk and to de-risk it. And the interesting bit is that all those platforms that I mentioned to you, they are very nicely profiled in the preclinical setting. So we have a huge amount of data and we are now looking to share the clinical risk moving forward.
Henk Jan Out
And these are patented platforms, and others cannot use it?
Christoph Korpus
No, absolutely, yes. So this is one thing. We have our own in house IP team that looks closely at generating innovative IP. And this is, of course, what we do.
Henk Jan Out
Right, right. So, how do you choose your payloads with all those platforms, if I understand the technology correctly?
Christoph Korpus
That’s the magic. Right, that’s the magic at the end. You have to see that we have around about 20 to 30 chemists in the company, right, that have more than 20 years of experience in the field. And they, the methodology, so to speak, what we are doing is that we look into drugs that have been used systemically but were too toxic. And then we make them even more toxic and then hook them to an ADC. So this is the overall concept.
Henk Jan Out
What’s the rationale behind making them even more toxic?
Christoph Korpus
Because only a limited number of payload at the end of the day reaches the tumor cell. This is the downside of every antibody drug conjugate. Only a very small fraction of the payload eventually reaches the tumor. So you have to make sure that that bit, which can be as low as 1% at the end of the day, that that bit really does the job. So you have to have something very potent in order to make it a drug.
Henk Jan Out
Yeah, but you choose a higher potency, and automatically that means higher toxicity, but that’s deliberately done in order to make use of the potency and the ADC.
Christoph Korpus
Yes, exactly. So this is what we have to do. So you have to show that it has a very low minimum efficacious dose in a species that you select. And then you also want to see a rather high, maximally tolerable dose. And in between this is where the magic happens, where you then have to optimize your antibody internalization rates. You have to look at the linker. So, do you use a tumor cleavable linker that only gets cleaved in the tumor microenvironment? I already talked about the masking concept that we apply. This is then when you can really tweak the ADC, and this is where you have to have the knowledge about it. So, this is nothing that you can do in one or two years, unfortunately.
Henk Jan Out
So, this is a privately owned company. Everything you’re doing costs a lot of money. I mean, your phase three trial undoubtedly must have cost us the fortune and was unfortunately not successful. So now you’re basically starting again in the preclinical stage, soon in the clinical stage. The funding is still there. You still have enough money, but you’re also looking for partners. Is that particularly to share the financial risks or to make use of knowledge of other partners? Why are you looking particularly for other partners?
Christoph Korpus
Yeah, it’s both, very honestly, right? So we have the luxury that Jacques Lemmens, who is the founder of Byondis and the former founder of Synthon as well, that he is fully committed, right? And that is a luxury to have, honestly, but it’s also a commitment, right? I personally see that also as a commitment because we have to look at means to A, diversify our shareholder base, which is something that we are open to discuss, and to find nondilutive funding in terms of licensing revenue, as every other biotech now does, right? Because of the history. But you mentioned an important point, which I always used to also highlight when I was on the buy side, and that is that there comes a value beyond the money, right? If you partner with a big pharma company or a mid-sized pharma company, doesn’t matter, you get a lot of expertise on top of the cash that you need to pursue the assets. So, regulatory expertise, IP, medical affairs, that is tremendously helpful to refine your clinical development programs, your plans, your regulatory strategy, the engagement with authorities. This is all incredibly helpful, and you cannot, I believe, do this as a small biotech in the same quality and pace that you can do it in a collaboration.
Henk Jan Out
Right. So you’re basically continuing your business development activities as you were doing already. This is probably still a major part of your CEO activities.
Christoph Korpus
Oh, yes, absolutely. And I do enjoy that, of course, but I also have a strong team that supports me in that endeavor.
Henk Jan Out
Is there a lot of interest in Byondis from others?
Christoph Korpus
Yes, and I’m very happy that I can say a clear yes, even though honestly it can always be more, right? As a CEO, which is why we’re out there. You see us now going on conferences, you see me now being here, you know, also taking part in webinars and those things. So the PR bit was a little bit underemphasized in the recent years, and this is what we are trying to change now. But you also, in the Byondis mindset, you want to go out when you have mature data, right? So we had to wait until our preclinical platforms are at this maturity stage, which they are right now. So we are at the very last preclinical maturation stage, which is good laboratory practice toxicity, GLP tox, which is the last kind of checkbox you have to do before you can go to the clinic.
Henk Jan Out
Right. So, you’re really looking for partners. You don’t look for a big company that just buys the whole company. How much do you want to do yourself? How much do you want to keep Byondis in the lead?
Christoph Korpus
Yes. I mean, at the end of the day, this is a question about governance, right? How do you orchestrate such a partnership? And this is something that we are willing to discuss. So, we are not dogmatic in that sense, for us, it is important that the science that we have now brought to this maturity stage really reaches a patient. So, the aim and the company ambition is to make hope real. And that is not a cheesy marketing phrase. This is really the mission of Byondis and what we want to achieve. And we will select partners based on that matched ambition first. And then, only second, we look into how such a transaction could look like.
Henk Jan Out
Right. So, five years from now, what will Byondis look like?
Christoph Korpus
In five years from now, Byondis will be a leading ADC powerhouse in Europe, if not in the world. We will have a lot of good phase 1B data at that point in time that underpins that we can really transform cancer care in solid tumors. This would be my hope that we can achieve that.
Henk Jan Out
Well, it’s certainly a fascinating story in those platforms. I have no knowledge about those whatsoever, but it’s the way you tell it, it sounds very promising. Well, I think we came to the end of the podcast. Thanks a lot, Christoph, for being with us today. I wish you very good luck with Byondis. I hope you’ll find more and more partners in the near future. And even more important is, of course, that those technologies actually will successfully make new ADCs there on the market and will benefit patients. It certainly looks very interesting. And to our listeners, thank you very much for joining us. In three weeks’ time, there will be a next podcast. Goodbye.
Dit was Leaders in Life Sciences, dankjewel voor het luisteren. Vond je iets van deze aflevering? Wij ontvangen graag jouw feedback. Wat houdt bijvoorbeeld jou bezig en over wie wil je meer horen? Laat het weten via een Apple of een Google review of stuur een berichtje via social media of natuurlijk gewoon per mail. Onze waardering is groot. Tot slot, nog dank aan onze partners. Dat zijn Pivot Park, Johnson & Johnson The Netherlands en Pedersen & Partners.
